Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 15/20 | 0.43 |
| ▸ | INSR | P06213 | 7/20 | 0.43 |
| ▸ | IGF1R | P08069 | 4/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.41 |
| ▸ | ROS1 | P08922 | 2/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30833022 | 1.00 | ALK (0.43) | ALKINSRIGF1REGFRAXL | |
| SCHEMBL24620341 | 0.91 | ALK (0.42) | ALKEGFRMAP4K1 | |
| SCHEMBL29791462 | 0.87 | ALK (0.56) | ALKINSRIGF1REGFRROS1 | |
| SCHEMBL24620243 | 0.87 | ALK (0.56) | ALKINSRIGF1REGFRROS1 | |
| SCHEMBL29791355 | 0.85 | ALK (0.46) | ALKINSRIGF1REGFR | |
| SCHEMBL24620283 | 0.85 | ALK (0.46) | ALKINSRIGF1REGFR | |
| SCHEMBL30833028 | 0.81 | ALK (0.54) | ALKINSRIGF1REGFRMAP3K7 | |
| SCHEMBL24620312 | 0.81 | ALK (0.54) | ALKINSRIGF1REGFRMAP3K7 | |
| SCHEMBL24620318 | 0.81 | ALK (0.54) | ALKINSRIGF1REGFRMAP3K7 | |
| SCHEMBL24620285 | 0.80 | ALK (0.46) | ALKINSRIGF1REGFRMAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | SINAI HEALTH SYSTEM (CA) | 2024-03-21 | — | — | US | claimed |
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | SINAI HEALTH SYSTEM (CA) | 2024-03-21 | — | — | US | disclosed |
| WO-2022147622-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | NUAK1, NUAK2, NEK1 | ALK 430/4885INSR 1031/4885IGF1R 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.